Industry Research Reports and Market Analysis at MindBranch.com Research Index | Publishers | My Account | Contact Us | About MindBranch
Welcome Guest  (Login/Register) |  0 items
  
Advanced Search > | Tips >
Contact a
Research Assistant
US 800-774-4410
or +1-240-747-3094
Search Assistance >

Home  > Healthcare  >  Pharmaceutical  >  Drug Discovery

Allergy Drug Pipeline and R&D 2009

Published Date: June 2009
Published By: Fuji-Keizai USA, Inc.
Page Count: 126
Order Code: R98-213
 
Questions About This Report
E-mail a Colleague
Printable Page
Fax Your Order
DescriptionTable of ContentsSimilar
Products

Executive Summary
1. Overview of the Global Allergy Medications Market
1.1 Allergies as a Medical Condition
1.1.1 Types of Allergies
1.1.2 Signs and Symptoms
1.1.3 Physiological Response
Table 1-1. Gell & Coombs Classification of Allergic Reactions
1.1.4 Prevalence
Table 1-2. Global Prevalence of Allergies
1.2 Medical Treatment of Allergies
1.2.1 Prescription Medications: Current Usage & Unmet Needs
Table 1-3. Leading Prescription Allergy Medications
1.2.1.1 U.S.
Table 1-4. U.S. DTC Advertising for Leading Rx and OTC Allergy Medications 2008
1.2.1.2 Europe
1.2.1.3 Japan
1.2.1.4 ROW
1.2.2 Non-Prescription Products: Current Usage & Unmet Needs
Table 1-5. Leading OTC Allergy Medications
1.2.2.1 U.S.
1.2.2.2 Europe
1.2.2.3 Japan
1.2.2.4 ROW
2 Global Allergy Medications Market Forecast 2008 - 2013
2.1 Rx Allergy Medications Market
2.1.1 Rx Allergy Drug Market Forecast by Product
2.1.1.1 Growth Drivers
Table 2-1. Rx Allergy Drug Market Forecast 2008 - 2013 by Product in $Million
2.1.1.2 Market Restraints
Table 2-2. U.S. Patent Expirations of Leading Prescription Allergy Drugs
2.1.2 Rx Allergy Drug Market Forecast by Region
Table 2-3. Rx Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
2.1.3 Rx Allergy Drug Market Forecast by Product Class
Table 2-4. Rx Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
Table 2-5. Rx Allergy Drug Market Product Segments Share, 2008 vs. 2013
Figure 2-1. Rx Allergy Drug Market Product Segments Share, 2008
Figure 2-2. Rx Allergy Drug Market Product Segments Share, 2013
2.2 OTC Allergy Drug Market
2.2.1 OTC Allergy Drug Market Forecast by Product
Table 2-6. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product in $Million
2.2.2 Growth Drivers
2.2.3 Market Restraints
2.2.4 OTC Allergy Drug Market Forecast by Region
Table 2-7. OTC Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
2.2.5 OTC Allergy Drug Market Forecast by Product Class
Table 2-8. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
2.3 Rx & OTC Allergy Drug Market
2.3.1 Rx & OTC Allergy Drug Market Forecast by Leading Manufacturers
Table 2-9. RX & OTC Allergy Drug* Sales of Leading Manufacturers, 2008 - 2013 in $Million
2.3.2 Rx & OTC Allergy Drug Market Share of Leading Drug Manufacturers
Table 2-10. Rx & OTC Market Shares of Leading Allergy Drug Manufacturers, 2008 vs. 2013
Figure 2-3. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2008
Figure 2-4. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2013
3. Allergy Drug Development: New Molecular Entities
Table 3-1. Key Characteristics of NMEs, Generics and Indication Expansions
3.1 All Allergy Drug Developers Position
3.1.1 Challenges in Allergy Drug Development
Table 3-2. All Allergy Drug Developers Product Position Overview
3.2 Key Products Under Development
Figure 3-1. Allergy Compounds Tested by Phase of Development
3.2.1 Antihistamines
3.2.1.1 Physiology and Mechanism of Action
3.2.1.2 Leading Antihistamine Allergy Drug Candidates
Table 3-3. Antihistamine Developers Product Position
3.2.2 Corticosteroids
3.2.2.1 Physiology and Mechanism of Action
3.2.2.2 Leading Corticosteroid Allergy Drug Candidates
Table 3-4. Corticosteroid Developers Product Position
3.2.3 Mast Cell Inhibitors
3.2.3.1 Physiology and Mechanism of Action
Figure 3-2. The Role of Mast Cells in Allergy Response
3.2.3.2 Leading Mast Cell Inhibitor Allergy Drug Candidates
Table 3-5. Mast Cell Inhibitors Developers Product Position
3.2.4 Allergy Immunotherapy
3.2.4.1 Physiology and Mechanism of Action
3.2.4.2 Leading Immunotherapy Allergy Drug Candidates
Table 3-6. Immunotherapy Developers Product Position
3.2.5 Vaccines
3.2.5.1 Physiology and Mechanism of Action
Figure 3-3. Production of TH2 Cytokines
3.2.5.2 Leading Allergy Vaccine Candidates
Table 3-7. Vaccine Developers Product Position
3.2.6 Other Types of Allergy Drugs
3.2.6.1 Physiology and Mechanism of Action
3.2.6.2 Other Leading Allergy Candidates
Table 3-8. Other Allergy Drug Developers Product Position
3.3 Global Market Forecast for New Allergy Drugs, 2008 - 2013
3.3.1 New Allergy Drug Market Forecast: Total and Segment Market
Table 3-9. Sales of New Allergy Drugs by Segment, 2008 - 2013
Figure 3-4. Market Shares of New Allergy Drugs by Segment, 2013
3.3.2 Growth Drivers
3.3.2.1 The Importance of Patents
3.3.3 Market Restraints
4. Allergy Drug Development: Indication Expansion
4.1 Indication Expansion for New Usage
Table 4-1. Selected Recent Allergy Drug Indication Expansions, U.S.
4.1.1 The Economic Benefits of Indication Expansion
Table 4-2. U.S. R&D Expenditure for New Medicines by the Pharma-Industry
4.1.2 Challenges in Allergy Drug Indication Expansion
Figure 4-1. Cost and Time Savings of Indication Expansions
4.2 Key Products Under Development
4.2.1 Database of Allergy Indication Expansion Initiatives by Company
Table 4-3. Selected Allergy Drug Indication Expansion Trials
4.2.2 Leading Areas of R&D Activity
4.2.2.1 Clarinex
4.2.2.2 Nasonex
4.2.2.3 Patanase
4.2.2.4 Singulair
4.2.2.5 Veramyst
4.2.2.6 Xolair
4.2.2.7 Xyzal
4.3 Global Market Forecast for Allergy Drug Indication Expansions
Table 4-4. Sales of Allergy Drug Indication Expansions, 2008 - 2013 in $ Million
Table 4-5. Product Market Share of Allergy Drug Indication Expansions, 2009 vs. 2013
Figure 4-2. Product Market Share of Allergy Drug Indication Expansions, 2009
Figure 4-3. Product Market Share of Allergy Drug Indication Expansions, 2013
4.3.1 Growth Drivers
4.3.2 Market Restraints
5. Allergy Drug Development: Basic Research
5.1 Basic Research Group & Activity
Table 5-1. Leading Organizations & Details for Basic Allergy Research
5.1.1 Challenges in Basic Allergy Research
Figure 5-1. National Institutes of Health Research Budget by Disease Area, Fiscal 2008
5.2 Key Areas of Investigation
Table 5-2. Recent Basic Research in the Field of Allergies
5.3 Unanswered Questions
6. Strategic Alliances for Allergy Drug Development
6.1 Types of Strategic Alliances
Figure 6-1. Comparison of Selected Deal Types
6.2 Current Strategic Alliances for Allergy Drug Development
Table 6-1. Ongoing Strategic Alliances for Allergy Drug Development
7. Activities of the Leading Allergy Drug Developers
Common Research Item:
1) Table: Product Profile:
2) R&D Strength and Capabilities
3) Marketed Allergy Drugs
4) Allergy Drug Pipeline
5) Table: Profile
7.1 Alcon Research
7.2 Allergy Therapeutics
7.3 AstraZeneca
7.4 GlaxoSmithKline
7.5 Johnson & Johnson
7.6 Meda AB
7.7 Merck
7.8 Novartis
7.9 Sanofi-Aventis
7.10 Schering-Plough
7.11 Sepracor
7.12 UCB Pharma
8. Total Allergy Drug Market: Forecasts & Directions
Table 8-1. Total Allergy Drug Sales by Segment, 2008 - 2013 in $Million
Figure 8-1. Total Allergy Drug Sales Growth by Segment, 2008 - 2013
Figure 8-2. Allergy Drug Market Share by Segment, 2008
Figure 8-3. Allergy Drug Market Share by Segment, 2013
9. Other Top Companies with Allergy Projects
Table 9-1. Other Top Companies with Late Stage Allergy Projects
Table 9-2. Other Top Companies with Early Stage Allergy Projects
10. Database of Allergy Drug Developers
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence

• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.

• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.

• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.

• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC

• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search

• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.

• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB

• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer

• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor



 

Privacy Policy | Terms & Conditions | Site Map | Return Policy | Help FAQs
Copyright © 1999-2008, All Rights Reserved, MindBranch.com
Trust-e Logo
Phone: 800-774-4410 (US) or +1-240-747-3094 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: support@mindbranch.com